Approaching psoriasis differently: Patient-physician relationships, patient education and choosing the right topical vehicle

Journal of Drugs in Dermatology

Volumn 9, Issue 8, 2010, Pages 908-911

  Feldman, Steven R ^a  

^a WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOBETASOL; CLOBETASOL PROPIONATE; VITAMIN D; DRUG VEHICLE; GLUCOCORTICOID;

AEROSOL; ARTICLE; CREAM; DERMATOLOGIST; DIAGNOSTIC ACCURACY; DOCTOR PATIENT RELATION; DRUG CHOICE; DRUG DOSAGE FORM COMPARISON; DRUG TOLERABILITY; EDUCATIONAL TECHNOLOGY; HUMAN; MAINTENANCE THERAPY; MEDICAL PRACTICE; OINTMENT; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT SATISFACTION; PHYSICIAN; PRESCRIPTION; PSORIASIS; TOPICAL TREATMENT; TREATMENT OUTCOME; CHEMISTRY; INTRADERMAL DRUG ADMINISTRATION; METHODOLOGY; PSYCHOLOGICAL ASPECT; VEHICLES;

ADMINISTRATION, CUTANEOUS; GLUCOCORTICOIDS; HUMANS; MEDICATION ADHERENCE; PATIENT EDUCATION AS TOPIC; PHYSICIAN-PATIENT RELATIONS; PSORIASIS; VEHICLES;

EID: 77955877814     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Strowd LC, Yentzer BA, Fleischer AB Jr, Feldman SR. Increasing use of more potent treatments for psoriasis. J Am Acad Dermatol. 2009;60(3):478-481.
2. Pearce DJ, Stealey KH, Balkrishnan R, et al. Psoriasis treatment in the United States at the end of the 20th century. Int J Dermatol. 2006;45:370-374.
3. Stern RS, Nijsten T, Feldman SR, et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004;9:136-139. (Pubitemid 38457271)
4. Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life: Results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001;137:280-284. (Pubitemid 32240779)
5. Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41:401-407. (Pubitemid 29418506)
6. Menter A, Griffiths CE. Current and future management of psoriasis. Lancet. 2007;370:272-284. (Pubitemid 47071926)
7. Rapp SR, Exum ML, Reboussin DM, et al. The physical, psychological and social impact of psoriasis. J Health Psychol. 1997;2:525-537. (Pubitemid 27475070)
8. Renzi C, Abeni D, Picardi A, et al. Factors associated with patient satisfaction with care among dermatological outpatients. Br J Dermatol. 2001;145:617-623.
9. Uhlenhake E, Kurkowski D, Feldman SR. Conversations on about psoriasis - What patients want and what physicians can provide. A qualitative look at patient and physician expectations. Accepted for publication. J Dermatolog Treat. 2009;1:1-7.
10. Uhas AA, Camacho FT, Feldman SR, Balkrishnan R. The relationship between physician friendliness and caring, and patient satisfaction findings from an Internet-based survey. The Patient. 2008;1:91-96.
11. Anderson R, Barbara A, Feldman S. What patients want: A content analysis of key qualities that influence patient satisfaction. J Med Pract Manage. 2007;22:255-261.
12. Kong MC, Camacho FT, Feldman SR, et al. Correlates of patient satisfaction with physician visit: Differences between elderly and non-elderly survey respondents. Health Qual Life Outcomes. 2007;5:62.
13. Renzi C, Tabolli S, Picardi A, et al. Effects of patient satisfaction with care on health-related quality of life: A prospective study. J Eur Acad Dermatol Venereol. 2005;19:712-718. (Pubitemid 41743324)
14. Storm A, Benfeldt E, Andersen SE, Serup J. Basic drug information given by physicians is deficient, and patients' knowledge low. J Dermatolog Treat. 2008;28:1-4.
15. Nijsten T, Rolstad T, Feldman SR, Stern RS. Members of the national psoriasis foundation: More extensive disease and better informed about treatment options. Arch Dermatol. 2005;141:19-26. (Pubitemid 40144436)
16. Lee IA, Maibach HI. Pharmionics in dermatology: A review of topical medication adherence. Am J Clin Dermatol. 2006;7:231-236. (Pubitemid 44231918)
17. Koehler AM, Maibach HI. Electronic monitoring in medication adherence measurement. Implications for dermatology. Am J Clin Dermatol. 2001;2:7-12.
18. Ali SM, Brodell RT, Balkrishnan R, Feldman SR. Poor adherence to treatments: A fundamental principle of dermatology. Arch Dermatol. 2007;143:912-915. (Pubitemid 47076491)
19. Feldman SR, Horn EJ, Balkrishnan R, et al International Psoriasis Council. Psoriasis: Improving adherence to topical therapy. J Am Acad Dermatol. 2008;59:1009-1016.
20. Storm A, Andersen SE, Benfeldt E, Serup J. One in 3 prescriptions are never redeemed: Primary nonadherence in an outpatient clinic. J Am Acad Dermatol. 2008;59:27-33.
21. Balkrishnan R, Carroll CL, Camacho FT, Feldman SR. Electronic monitoring of medication adherence in skin disease: Results of a pilot study. J Am Acad Dermatol. 2003;49:651-654. (Pubitemid 37210278)
22. Carroll CL, Feldman SR, Camacho FT, et al. Adherence to topical therapy decreases during the course of an 8-week psoriasis clinical trial: Commonly used methods of measuring adherence to topical therapy overestimate actual use. J Am Acad Dermatol. 2004;51:212-216.
23. Brown KK, Rehmus WE, Kimball AB. Determining the relative importance of patient motivations for nonadherence to topical corticosteroid therapy in psoriasis. J Am Acad Dermatol. 2006;55:607-613. (Pubitemid 44436629)
24. Housman TS, Mellen BG, Rapp SR, et al. Patients with psoriasis prefer solution and foam vehicles: A quantitative assessment of vehicle preference. Cutis. 2002;70:327-332. (Pubitemid 41757440)
25. Warino L, Balkrishnan R, Feldman SR. Clobetasol propionate for psoriasis: Are ointments really more potent? J Drugs Dermatol. 2006;5:527-532.
26. Jarratt MT, Clark SD, Savin RC, et al. Evaluation of the efficacy and safety of clobetasol propionate spray in the treatment of plaquetype psoriasis. Cutis. 2006;78:348-354. (Pubitemid 44952097)
27. Stein L. Clinical studies of a new vehicle formulation for topical corticosteroids in the treatment of psoriasis. J Am Acad Dermatol. 2005;53:S39-S49. (Pubitemid 40828180)
28. Koo JY. Relevance of the COBRA trial in current psoriasis practice. Cutis. 2007;80(5 Suppl):4-11.
29. Feldman SR. Effectiveness of clobetasol propionate spray 0.05% added to other stable treatments: Add-on therapy in the COBRA trial. Cutis. 2007;80(5 Suppl):20-28.
30. Menter A. Topical monotherapy with clobetasol propionate spray 0.05% in the COBRA trial. Cutis. 2007;80(5 Suppl):12-19.
31. Kurkowski Market Research. Dermatologists' Reactions to the COBRA Study. Galderma Laboratories, 2008.
32. Koo JY. New developments in topical sequential therapy for psoriasis. Skin Therapy Lett. 2005;10:1-4.